If you had looked at Waterdrop on 1 January and decided to skip a story built around AI tools like DeepSeek and KEYI.AI, you might feel you dodged something. Holding Waterdrop from the start of the year would have meant a 44.2% loss, including dividends. That is a painful result. The real question is which assumption on record at the time, from bullish AI efficiency hopes to bearish regulatory and demographic worries, might have signalled this risk clearly enough to challenge.
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
This theme extends beyond Waterdrop. See which of 34 healthcare AI stocks may still merit a closer look.
The shares cost US$1.9 at the start of the period, and any investor looking at Waterdrop then was really choosing between two sharply different but still reasonable stories.
On the bullish side, one narrative put Fair Value at US$2.21, built on AI tools like DeepSeek lifting sales efficiency, with assumptions that revenue would grow 15.1% and profit margins would reach 15.2% within about three years.
The bearish view anchored Fair Value at US$1.36, focused on stricter Chinese regulation and aging demographics raising compliance costs and limiting the future insurance market Waterdrop could serve.
Waterdrop's 2025 ESG report highlighted KEYI.AI improving underwriting efficiency, which supported the bullish argument that AI tools could lift productivity. The Q2 2026 figures told a tougher story. Revenue reached C¥1,448.219m against C¥837.959m a year earlier, yet net income fell and net margin moved from 16.7% to 8.7%. The evidence cut both ways.
The live assumption here was that AI efficiency would feed through to profitability. When you weigh a similar claim elsewhere, track net margin alongside AI announcements and check whether profit per unit of revenue actually holds up.
Waterdrop now trades at US$1.02, and the selected Narrative sees Fair Value above that level. The current view leans on AI driven insurance tools, inclusive health coverage, and the E Find platform as the core economic engine.
For the recent fall to look like an opening rather than a warning, a buyer would need confidence that heavier sales, marketing, and AI spending genuinely convert into a larger, sustainably profitable customer base.
"The main thing that has to go right is that higher sales and marketing and AI-related R&D spending translate into a larger, profitable insurance customer base rather than lasting margin pressure."
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there
Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.
That is three of the list. See the full list of 29 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com